These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 23800326)

  • 41. Anti-retrovirals for treatment and prevention--time for new paradigms in our response to the HIV/AIDS epidemic?
    Abdool Karim Q; Bayer R
    Dev World Bioeth; 2013 Aug; 13(2):ii-iii. PubMed ID: 23865982
    [No Abstract]   [Full Text] [Related]  

  • 42. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.
    Spinner CD; Boesecke C; Zink A; Jessen H; Stellbrink HJ; Rockstroh JK; Esser S
    Infection; 2016 Apr; 44(2):151-8. PubMed ID: 26471511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective.
    Conniff J; Evensen A
    J Am Board Fam Med; 2016; 29(1):143-51. PubMed ID: 26769887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Access to HIV care and treatment for migrants between Lesotho and South Africa: a mixed methods study.
    Faturiyele I; Karletsos D; Ntene-Sealiete K; Musekiwa A; Khabo M; Mariti M; Mahasha P; Xulu T; Pisa PT;
    BMC Public Health; 2018 May; 18(1):668. PubMed ID: 29843667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Women and ARV-based HIV prevention - challenges and opportunities.
    Geary CW; Bukusi EA
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19356. PubMed ID: 25224621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Samuel R; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
    J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Willingness to use PrEP among female university students in Lesotho.
    Karletsos D; Greenbaum CR; Kobayashi E; McConnell M
    PLoS One; 2020; 15(3):e0230565. PubMed ID: 32231394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
    Blumenthal J; Haubrich R
    Expert Opin Pharmacother; 2013 Sep; 14(13):1777-85. PubMed ID: 23800167
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.
    Janes H; Corey L; Ramjee G; Carpp LN; Lombard C; Cohen MS; Gilbert PB; Gray GE
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):645-656. PubMed ID: 29732896
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention.
    Cáceres CF; Koechlin F; Goicochea P; Sow PS; O'Reilly KR; Mayer KH; Godfrey-Faussett P
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19949. PubMed ID: 26198341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
    Landovitz RJ
    Top Antivir Med; 2015; 23(2):85-90. PubMed ID: 26200708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.
    Hankins C; Macklin R; Warren M
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19973. PubMed ID: 26198343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PrEP Stigma: Implicit and Explicit Drivers of Disparity.
    Golub SA
    Curr HIV/AIDS Rep; 2018 Apr; 15(2):190-197. PubMed ID: 29460223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modeling HIV Pre-Exposure Prophylaxis.
    Straubinger T; Kay K; Bies R
    Front Pharmacol; 2019; 10():1514. PubMed ID: 32082142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uptake of PrEP for HIV slow among MSM.
    Kirby T; Thornber-Dunwell M
    Lancet; 2014 Feb; 383(9915):399-400. PubMed ID: 24494225
    [No Abstract]   [Full Text] [Related]  

  • 57. Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs.
    Sachdev DD; Stojanovski K; Liu AY; Buchbinder SP; Macalino GE
    Clin Infect Dis; 2014 Jun; 58(12):1786-7. PubMed ID: 24729556
    [No Abstract]   [Full Text] [Related]  

  • 58. Invited commentary: every good randomization deserves observation.
    Westreich D; Edwards JK
    Am J Epidemiol; 2015 Nov; 182(10):857-60. PubMed ID: 26487342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reply to Sachdev et al.
    Karris MY; Beekmann SE; Mehta SR; Polgreen PM
    Clin Infect Dis; 2014 Jun; 58(12):1788. PubMed ID: 24729555
    [No Abstract]   [Full Text] [Related]  

  • 60. Antiretroviral vaginal gel shows promise against HIV.
    Baleta A
    Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.